Effects of elexacaftor-tezacaftor-ivacaftor discontinuation in cystic fibrosis
Published inRespiratory medicine and research, vol. 82, 100972
Publication date2022-11
First online date2022-11-02
Keywords
- Adherence
- Bronchiolitis
- Elexacaftor–tezacaftor–ivacaftor
- Withdrawal
- Humans
- Cystic Fibrosis / drug therapy
- Cystic Fibrosis / genetics
- Pyrazoles / adverse effects
Affiliation entities
Citation (ISO format)
MITROPOULOU, Georgia et al. Effects of elexacaftor-tezacaftor-ivacaftor discontinuation in cystic fibrosis. In: Respiratory medicine and research, 2022, vol. 82, p. 100972. doi: 10.1016/j.resmer.2022.100972
Main files (1)
Article (Published version)
Identifiers
- PID : unige:175728
- DOI : 10.1016/j.resmer.2022.100972
- PMID : 36371896
Additional URL for this publicationhttps://www.sciencedirect.com/science/article/pii/S2590041222000873
Journal ISSN2590-0412
